These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22020210)

  • 1. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?
    Steffens S; Grünwald V; Ringe KI; Seidel C; Eggers H; Schrader M; Wacker F; Kuczyk MA; Schrader AJ
    Oncologist; 2011; 16(11):1565-71. PubMed ID: 22020210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.
    Ladoire S; Bonnetain F; Gauthier M; Zanetta S; Petit JM; Guiu S; Kermarrec I; Mourey E; Michel F; Krause D; Hillon P; Cormier L; Ghiringhelli F; Guiu B
    Oncologist; 2011; 16(1):71-81. PubMed ID: 21212435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy.
    Mizuno R; Miyajima A; Hibi T; Masuda A; Shinojima T; Kikuchi E; Jinzaki M; Oya M
    Med Oncol; 2017 Apr; 34(4):47. PubMed ID: 28213730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
    Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
    Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
    Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
    AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
    Buchler T; Poprach A; Bortlicek Z; Lakomy R; Chloupková R; Vyzula R; Zemanova M; Kopeckova K; Svoboda M; Slaby O; Kiss I; Studentova H; Hornova J; Fiala O; Kopecky J; Finek J; Dusek L; Melichar B;
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1047-e1053. PubMed ID: 28720439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).
    Seidel C; Busch J; Weikert S; Steffens S; Bokemeyer C; Grünwald V
    Br J Cancer; 2013 Dec; 109(12):2998-3004. PubMed ID: 24169357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
    Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
    Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
    Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in the treatment of advanced renal cell carcinoma.
    Seront E; Machiels JP
    Recent Pat Anticancer Drug Discov; 2009 Jun; 4(2):146-56. PubMed ID: 19519537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.